Table 1.
Descriptive Statistics
| Variable | Outside CTN (n=766) | Within CTN (n=240) | Significance (p) |
|---|---|---|---|
| Adopted buprenorphinea | 11.1 | 20.0 | <.001 |
| Adopted motivational incentivesa | 31.2 | 33.8 | ns |
| Operating revenues from public sources (M) | 47.8 | 51.9 | ns |
| For-profit structure | 17.9 | 12.4 | <.029 |
| Accredited by JCAHO or CARF | 48.1 | 65.6 | <.001 |
| Surveys buyers, suppliers, or both | 77.3 | 70.1 | <.016 |
| Offers detoxification services | 29.1 | 18.6 | <.001 |
| Outpatient-only services | 46.9 | 52.7 | ns |
| FTEs (M) | 34.0 | 33.7 | ns |
| Physician(s) on staff or contract | 69.3 | 71.8 | ns |
| Master's level counselors | 44.5 | 44.5 | ns |
| Primary opiate clientsb | 15.9 | 41.8 | <.000 |
| Program experience in clinical research | 41.7 | 41.1 | ns |
a
Adoption of buprenorphine and incentives was measured on 6-month follow-up interview. All other variables were measured at baseline interview.
b
Removal of methadone units from CTN sample reduced the average opiate clients to 18.3% of CTN caseloads, which is still significantly higher than in non-CTN settings (p<.05).